MetaCap

Lyell Immunopharma Inc. (LYEL)

NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.80+0.22 (+1.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LYEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$441.82M
EPS (TTM)
-$12.61
52-week range
7.20 – 45.00
Day range
13.30 – 14.30
Volume / Avg
171.09K / 174.76K
Beta
—

52-week range

$7.20$45.00

LYEL stock today

On Nov 20, LYEL ended the session at $13.80, adding $0.22 (1.62%), versus the S&P 500's 3.70% decline. At this level, LYEL sits near the bottom of its 52-week range of $7.20 to $45.00: 69.3% below the high, set on Dec 22, 2025 and 91.8% above the low. LYEL is down 55.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.9%.

Lyell Immunopharma has posted a net loss over the last twelve months (EPS of -$12.61), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lyell Immunopharma

Company profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Lynn Seely M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
161
IPO year
2021
Website
lyell.com

Financial highlights

Full financials

In fiscal 2025, Lyell Immunopharma generated $36,000 in revenue, down 41.0% from fiscal 2024, its first annual decline since 2024. Lyell Immunopharma reported a net loss of $274.4 million, compared with a loss of $343.0 million a year earlier. Operating margin was -748344.4%.

Lyell Immunopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$36.00K$61.00K$130.00K$84.68M$10.65M
Growth-40.98%-53.08%-99.85%+695.15%+37.31%
Net income$-274.45M$-342.99M$-234.63M$-183.12M$-250.22M
EPS (diluted)$-16.06$-26.23$-18.70$-0.74$-1.84

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$37.63+172.68%

  • Strong buy 2
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 1

Target range

Low $12.00High $49.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-1.86 vs $-2.06
Surprise
+9.71%

LYEL news

All LYEL news

Lyell Immunopharma peers

Health Care sector
LYEL peer companies
CompanyPrice% ChgMarket capCompare
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs LYEL
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs LYEL
EOLSEvolus Inc.6.52-6.86%$431.55Mvs LYEL
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs LYEL
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs LYEL
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs LYEL
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs LYEL
ARVNArvinas Inc.6.46-4.15%$423.03Mvs LYEL

Indexes, lists and sector

Lyell Immunopharma stock FAQ

What is Lyell Immunopharma's stock price today?

LYEL last traded at $13.80 as of Nov 20, 4:00 PM EST, up 1.62% on the day. Prices are delayed at least 15 minutes.

Does Lyell Immunopharma pay a dividend?

No. Lyell Immunopharma does not currently pay a regular cash dividend.

Who is Lyell Immunopharma's CEO?

Dr. Lynn Seely M.D., Ph.D. is the chief executive officer of Lyell Immunopharma Inc., which has about 161 employees.

Has LYEL ever split its stock?

Yes. The most recent LYEL stock split was a 1-for-20 split on Jun 2, 2025.

What is the LYEL 52-week high?

The 52-week high for LYEL is $45.00 and the 52-week low is $7.20. The stock is currently 69.3% below its high.

Compare LYEL